Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
Clinical trial NCT03927105 · COMPLETED
Trial details
- NCT number
- NCT03927105
- Sponsor
- University of Michigan Rogel Cancer Center
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-04-25
- Primary completion
- 2019-11-01
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.